Brigit M. Te Pas

Brigit M. Te Pas

Auto-generated profile, based on publicly available information

Brigit M. Te Pas

Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2025 in Nature Immunology
Verified
Journal Article
Open access
PDF file
FKFarid Keramati
Farid Keramati
GLGuus P. Leijte
Guus P. Leijte
NBNiklas Bruse
Niklas Bruse
IGInge Grondman
Inge Grondman
EHEhsan Habibi
Ehsan Habibi
MKMatthijs Kox
Matthijs Kox
Systemic inflammatory conditions are classically characterized by an acute hyperinflammatory phase, followed by a late immunosuppressive phase that elevates the susceptibility to secondary infections. Comprehensive mechanistic understanding of these phases is largely lacking. To address this gap, we leveraged a controlled, human in vivo model of lipopolysaccharide (LPS)-induced systemic inflammation encompassing both phases. Single-cell RNA sequencing during the acute hyperinflammatory phase identified an inflammatory CD163 + SLC39A8 + CALR + monocyte-like subset (infMono) at 4 h post-LPS administration. The late immunosuppressive phase was characterized by diminished expression of type I interferon (IFN)-responsive genes in monocytes, impaired myelopoiesis and a pronounced attenuation of the immune response on a secondary LPS challenge 1 week after the first. The infMono gene program and impaired myelopoiesis were also detected in patient cohorts with bacterial sepsis and coronavirus disease. IFNβ treatment restored type-I IFN responses and proinflammatory cytokine production and induced monocyte maturation, suggesting a potential treatment option for immunosuppression.

17 February 2026 in Nature Immunology
Verified
Journal Article
Open access
PDF file
EHEvelyn S. Hanemaaijer
Evelyn S. Hanemaaijer
KMKonradin F. Müskens
Konradin F. Müskens
IKIreen J. Kal
Ireen J. Kal
LCLi-Ting Chen
Li-Ting Chen
BPBrigit M. Te Pas
Brigit M. Te Pas
MBMirjam Belderbos
Mirjam Belderbos
Childhood is a critical period for hematopoietic development and susceptibility to hematologic disease. Here we generated a multimodal single-cell atlas of healthy human bone marrow, capturing mRNA and surface protein expression in 90,710 cells, including over 20,000 hematopoietic stem and progenitor cells (HSPC) and mesenchymal stromal cells (MSC) from nine donors ranging from infancy to young adulthood (2–32 years). Young pediatric (YP) bone marrow (<10 years) was compositionally and molecularly distinct from adolescent and young adult (AYA) bone marrow (≥13 years), with hematopoietic output shifting from B cell dominance in YP bone marrow to myeloid and T cell bias in AYA bone marrow. Spatial transcriptomics of six bone marrow biopsies (0–23 years) confirmed these age-dependent changes. Two lymphoid progenitor (LyP) subsets regulated this lineage shift: CD127+ LyP cells with B cell-biased output were enriched before age 10, whereas CD127− LyP cells with combined lymphoid and myeloid features predominated thereafter. Stromal signaling showed corresponding age-dependent changes, with increased interleukin-7 production by bone marrow MSC in YP compared to AYA, indicating niche-mediated regulation of HSPC lineage potential during ontogeny. This single-cell atlas provides a comprehensive resource for understanding hematopoietic development and early-life origins of hematologic disease.

13 January 2025 in Blood Cancer Discovery
Verified
Journal Article
Open access
KMKonradin F. Müskens
Konradin F. Müskens
NWNienke Wieringa
Nienke Wieringa
MBMaaike G.J.M. van Bergen
Maaike G.J.M. van Bergen
JBJoëll E. Bense
Joëll E. Bense
BPBrigit M. Te Pas
Brigit M. Te Pas
MBMirjam Belderbos
Mirjam Belderbos
In pediatric hematopoietic cell transplantation (HCT) recipients, transplanted donor cells may need to function far beyond normal human lifespan. In this study, we investigated the risk of clonal hematopoiesis (CH) in 144 pediatric long-term HCT survivors and 258 nontransplanted controls. CH was detected in 16% of HCT recipients and 8% of controls at variant allele frequencies of 0.01 to 0.31. Mutations were predominantly in DNMT3A (80%) and TET2 (20%). Older hematopoietic age (OR: 1.07; P < 0.001) and the HCT procedure (OR: 2.53; P = 0.02) independently increased the risk of CH, indicating both aging- and transplantation-induced effects. Large clones (variant allele frequency >0.10) were found exclusively in HCT recipients. Notably, CH was also detected within 15 years after a cord blood HCT. Inflammatory processes around graft infusion were associated with CH presence. Future studies are required to track the evolution of posttransplant CH and its impact on future cardiovascular diseases, second malignancies, and overall survival. Significance: As survival of HCT recipients continues to improve, late treatment effects gain importance. We demonstrate that pediatric HCT recipients show increased risk of CH compared with age-matched controls. Prospective studies are crucial to understand the clinical implications of posttransplant CH in this young population.

17 June 2026
Verified
Other
Open access
KMKonradin F. Müskens
Konradin F. Müskens
NWNienke Wieringa
Nienke Wieringa
MBMaaike G.J.M. van Bergen
Maaike G.J.M. van Bergen
JBJoëll E. Bense
Joëll E. Bense
BPBrigit M. Te Pas
Brigit M. Te Pas
MBMirjam Belderbos
Mirjam Belderbos
In pediatric hematopoietic cell transplantation (HCT) recipients, transplanted donor cells may need to function far beyond normal human lifespan. In this study, we investigated the risk of clonal hematopoiesis (CH) in 144 pediatric long-term HCT survivors and 258 nontransplanted controls. CH was detected in 16% of HCT recipients and 8% of controls at variant allele frequencies of 0.01 to 0.31. Mutations were predominantly in DNMT3A (80%) and TET2 (20%). Older hematopoietic age (OR: 1.07; P < 0.001) and the HCT procedure (OR: 2.53; P = 0.02) independently increased the risk of CH, indicating both aging- and transplantation-induced effects. Large clones (variant allele frequency >0.10) were found exclusively in HCT recipients. Notably, CH was also detected within 15 years after a cord blood HCT. Inflammatory processes around graft infusion were associated with CH presence. Future studies are required to track the evolution of posttransplant CH and its impact on future cardiovascular diseases, second malignancies, and overall survival.Significance:As survival of HCT recipients continues to improve, late treatment effects gain importance. We demonstrate that pediatric HCT recipients show increased risk of CH compared with age-matched controls. Prospective studies are crucial to understand the clinical implications of posttransplant CH in this young population.

17 June 2026
Verified
Other
Open access
KMKonradin F. Müskens
Konradin F. Müskens
NWNienke Wieringa
Nienke Wieringa
MBMaaike G.J.M. van Bergen
Maaike G.J.M. van Bergen
JBJoëll E. Bense
Joëll E. Bense
BPBrigit M. Te Pas
Brigit M. Te Pas
MBMirjam Belderbos
Mirjam Belderbos
Characteristics of total and matched cohorts

17 June 2026
Verified
Other
Open access
PDF file
KMKonradin F. Müskens
Konradin F. Müskens
NWNienke Wieringa
Nienke Wieringa
MBMaaike G.J.M. van Bergen
Maaike G.J.M. van Bergen
JBJoëll E. Bense
Joëll E. Bense
BPBrigit M. Te Pas
Brigit M. Te Pas
MBMirjam Belderbos
Mirjam Belderbos
Overview of screening and inclusion